NATCAPSUQ

Natural Capsules Limited

· Pharma & Health
₹ CrorePeersNECLIFEAAREYDRUGSBALPHARMAALPAKREBSBIOMEDICAMEQMEDICOVINEETLAB
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt103.8114.3114.3
Net Debt103.1114.1114.1
Total Debt/Equity0.400.490.49
Net Debt/Equity0.400.490.49
Total Debt/EBITDA5.93-73.31-73.31
Net Debt/EBITDA5.89-73.17-150.32
Interest Coverage (EBIT/Interest)1.33-1.71-1.71
Total Debt/Total Capital %28.7632.7632.76
As Filed — company-reported covenants
Debt/Equity (as filed)40.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.